Research programme: peroxidase antimicrobial therapeutics - Exoxemis

Drug Profile

Research programme: peroxidase antimicrobial therapeutics - Exoxemis

Alternative Names: C-101 - Exoxemis

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Exoxemis
  • Class Peroxidases
  • Mechanism of Action Reactive oxygen species stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Bacterial infections

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Bacterial-infections in USA (Topical)
  • 11 Sep 2012 Early research in Bacterial infections in USA (Topical)
  • 11 Sep 2012 Antimicrobial data from an early research study presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2012)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top